Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses

BACKGROUND: Neoadjuvant chemotherapy (NAC) is a standard treatment for stage II/III breast cancer patients, and response to NAC is a useful prognostic marker. Since its introduction, 6–8 cycles of NAC has become the standard regimen to improve the outcome of these patients. The purpose of this study...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Cancer
Autors principals: Yang, Yaewon, Im, Seock-Ah, Keam, Bhumsuk, Lee, Kyung‑Hun, Kim, Tae‑Yong, Suh, Koung Jin, Ryu, Han Suk, Moon, Hyeong-Gon, Han, Sae‑Won, Oh, Do‑Youn, Han, Wonshik, Kim, Tae‑You, Park, In Ae, Noh, Dong-Young
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2016
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4955253/
https://ncbi.nlm.nih.gov/pubmed/27444430
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2500-1
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars